skip navigation, go to content
Neuroprotection Exploratory Trials in Parkinson's Disease: NET-PD National Institute of Neurological Disorders and Stroke logo
National Institutes of Health
The content on this page is archived and provided for reference purposes only. NINDS no longer updates this information, but it may be useful as a reference or resource.
[Enrolling now: FS-Zone]
[Am I eligible?]
[Where can I participate?]
[Bladder cancer risk]
[En Espaņol]
[For more information, call toll free 1-800-352-9424 email or visit] Learn more about NET-PD clinical trials for Parkinson's Disease
[What is the FS-Zone study?]

The NINDS NET-PD investigators are studying the effects of the drug pioglitazone taken once daily. In the study, 216 men and women with early Parkinson's disease are receiving pioglitazone or a matching placebo (an inactive substance). Researchers are comparing two doses of pioglitazone,15 and 45 milligrams, with a placebo to find out how it effects the progression of Parkinson's disease over 44 weeks.

Pioglitazone is currently approved by the FDA to treat type II diabetes. It may be useful in slowing the progression of Parkinson's disease.

This study also is exploring the effect of pioglitazone on motor skills, cognitive function, mood, and biomarkers. Biomarkers are biological characteristics or features that can provide information on how the disease changes over time and may be useful in developing new treatments and improving clinical care in the future.

[Participating in a clinical study allows you to play an active role in developing future treatments for Parkinson's disease.]

NET-PD Home | Enrolling now: FS-Zone | Am I Eligible?
Where Can I Participate? | Bladder cancer risk | FS-Zone: En Español
NINDS Home | Download Adobe Reader

U.S. Department of Health and Human Services logo     National Institutes of Health logo logo

NIH...Turning Discovery Into Health®